Latest From Biotech Now

Patently Biotech’s Top 5 Articles of 2012

By Vectorportal

2012 has been an eventful year for biotech IP issues.  Below are the top 5 articles and from Patently Biotech in 2012.  Click on the links to read the full articles. 1.  The Real Reason Why Salk Refused to Patent the Polio Vaccine A guest writer in a recent article in the Wall Street Journal repeated the oft quoted Jonas Salk statement about his Polio vaccine: “There is no patent.  Could you patent the sun?”  Many use this statement Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: ,

2012 Biotech Gift Guide

xmas-presents

Welcome to this year’s BIOtechNOW Gift Guide, our most loved biotech gift ideas from 2012 and beyond. Here you’ll find gifts that track your genetic history, interesting biotech books, and art! So whether you’re looking for a last-minute gift idea or a way to blow part of that holiday bonus consider this your guide to yuletide biotech bliss! Add your suggestions in the comments! 23andMe 23andMe is a DNA analysis service providing information and tools Read More >

Corporate  |  Leave a comment  |  Email This Post
Tags: , , , ,

Harder, Better, Faster, Stronger: Takeaways from Partnering For Cures 2012

Drug Manufacturing

The chorus to Kanye West’s 2007 chart-topper Stronger can teach us volumes about speeding drug development. Harder:  Drug development is challenging.  It takes over 10 years and more than $1 billon to bring a therapy through the product pipeline, from the research lab to clinical trials to FDA approval to prescription to patients suffering from the disease. The FDA approved over 30 innovative drugs last year, including more than 10 new treatments for cancer—a good Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

FDASIA: A Step Forward for Patients

fdasia-panel

Earlier this year, Congress passed and President Obama signed the FDA Safety and Innovation Act (FDASIA) which included a re-authorization of the Prescription Drug User Fee Act (PDUFA). PDUFA provides essential funding to the FDA by authorizing the agency to charge user fees to companies seeking to have products reviewed. Originally enacted in 1992, it must be reauthorized every 5 years. Sara Radcliffe, executive vice president of health at BIO, moderated a panel of experts and advocates Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , ,

Delivering on the Promise of Personalized Medicine

185x185_ad_btn_home

As sequencing moves out of the lab and into the clinic, a host of players must get involved to make our collective promises of personalized medicine a reality. CEOs, entrepreneurs, researchers, clinicians, regulators and payers need to work together to take on the next challenges in the implementation of personalized medicine. Some of those challenges include: Cost vs. Benefit: How do we define and benefit from transformational technologies? Form vs. Function: What about the less Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,